Regardless of PD-L1 status in the ATTRACTION-2 trial, nivolumab monotherapy improved overall survival in patients with advanced gastric cancer by 5.26 months (95% CI 4.60–6.37), but the ORR was only 11.2% (95% CI: 7.77–15.6) [10]. Here, CD274 is linked to gastric cancer.